Locally advanced rectal cancer: time for precision therapeutics

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• The 30th anniversary of the NSABP-R01 trial highlights its impact on locally advanced rectal cancer treatment.
• This landmark study demonstrated the efficacy of pelvic radiation, reducing local recurrence rates.
• Multimodal therapy has evolved significantly over three decades, improving patient outcomes.

Purpose of the Study:

• To review the evolution of rectal cancer treatment since the NSABP-R01 trial.
• To discuss the current standard of care for locally advanced rectal cancer.
• To explore alternative strategies for individualized therapy based on recurrence risk.

Main Methods:

• Review of historical data and landmark trials, specifically NSABP-R01.
• Analysis of current treatment standards, including neoadjuvant chemoradiation, total mesorectal excision (TME), and adjuvant chemotherapy.
• Discussion of evolving treatment paradigms and risk stratification.

Main Results:

• The NSABP-R01 trial reduced local recurrence from 25% to 16% with the addition of pelvic radiation.
• Current trimodality therapy (neoadjuvant chemoradiation with 5-fluorouracil (5-FU) and TME, followed by adjuvant chemotherapy with 5-FU and oxaliplatin) achieves local recurrence rates below 10%.
• Despite improvements, distant relapse rates remain high at 30% to 40%.

Conclusions:

• Multimodal therapy has dramatically improved rectal cancer management, establishing a new standard of care.
• While local control has been optimized, distant metastasis remains a significant challenge.
• Individualizing treatment strategies based on patient-specific recurrence risk is crucial for further progress.